Ultragenyx Pharmaceutical Inc.
RARE
$29.87
-$0.44-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -532.93M | -549.58M | -569.18M | -558.99M | -585.12M |
| Total Depreciation and Amortization | 35.45M | 35.69M | 35.54M | 34.68M | 33.12M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.11M | 110.65M | 105.53M | 101.25M | 106.09M |
| Change in Net Operating Assets | -24.87M | 13.30M | 13.92M | 4.47M | -23.56M |
| Cash from Operations | -421.25M | -389.94M | -414.19M | -418.59M | -469.47M |
| Capital Expenditure | -6.06M | -5.60M | -7.49M | -8.44M | -10.52M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.35M | 13.29M | -10.28M | -219.08M | 122.79M |
| Cash from Investing | 18.30M | 7.69M | -17.77M | -227.52M | 112.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 91.17M | 392.40M | 392.24M | 719.67M | 740.73M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.00M | 7.06M | 7.00M | 7.00M | 0.00 |
| Cash from Financing | 98.17M | 399.46M | 399.24M | 726.67M | 740.73M |
| Foreign Exchange rate Adjustments | 3.16M | -398.00K | -2.53M | 1.05M | -940.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -301.62M | 16.81M | -35.24M | 81.61M | 382.59M |